# Maximum insights

## “I can’t treat what I can’t see”

Bacteria appear red in image

MolecuLight
i:X

Distributed by smith&nephew

**©2018 MolecuLight® Inc.** All Rights Reserved. GMC00380 Rev 1.2

The MolecuLight *i:X*™ Imaging Device is approved by Health Canada (Medical License #95784) and has CE marking (Certificate #G1160292355002) for sale in Canada and the European Union. The MolecuLight *i:X*™ Imaging Device is not available in the US. MolecuLight® and Look to Heal® are Registered Trademarks in Canada, the US, and the EU.

Traditional signs and symptoms of wound infection can often lack sufficient accuracy to guide clinical decisions.[1]

- Are bacteria present that may delay wound healing?
- Do I know where to collect an accurate sample?
- Is cleansing effective and sufficient?
- Where should I focus debridement and how much should I debride?
- Are the bacteria cleared and the wound ready for dressing?
- Is an antimicrobial dressing necessary?
- Which dressing should I use?
- Am I objectively tracking progress?
- Is the treatment working?

## The high cost of wound care

**1.5–2 million people**
living with a chronic wound across Europe[2]

**16%**
16% of chronic wounds[2]

**1-1+ yrs**
1 year or more remained unhealed

Heavy bioburden/infection is a major cause of non-healing & a significant contributor to increasing costs[3,4]

> It's vital that health care providers seek more efficient ways of managing resource intensive patients with wounds.[2]

# See what you're missing with MolecuLight *i:X*™

## This may help empower your clinical practice[5]

Quickly, safely, and easily visualize fluorescent bacteria and measure wound surface area at the point of care.[6,13,14]

## How does it work?

Leveraging the principle of fluorescence, MolecuLight *i:X* emits safe violet light which causes bacteria ≥ $10^4$ CFU/g to fluoresce.[6]

# What does MolecuLight *i:X* do?



*Bacteria appear red in image*

## Visualize fluorescent bacteria in real-time

- Locate fluorescent bacteria instantly[6]
- Target wound debridement and cleansing[6,7,8]
- Optimize wound-bed preparation prior to advanced treatments[15]
- Guide sampling and biopsy[6,9-11]
- Guide antibiotic decision making[11,12]
- Support more responsible antimicrobial stewardship[11,12]
- Support education and patient engagement[7,8]
- Bacteria appear red in image. (*Pseudomonas aeruginosa* would appear cyan if present.)




## Document wound status

- Measure wound surface area[13,14]
- Capture and save images[6,7]
- Track and document progress of wound over time[5,6]

# What difference does MolecuLight *i:X*™ make?

**9X**
**faster healing[6]**

Incorporating the MolecuLight *i:X* wound assessment tool into standard care helps clinicians identify and treat fluorescent bacteria which has been shown to reduce the average closure time of chronic wounds from 200 to 22 days (9x improvement over standard care).[6]

## May accelerate wound closure[6]

Accurate wound assessment leads to more appropriate wound treatment which may accelerate wound closure.*




MolecuLight *i:X* guided treatment increased the rate of wound healing (statistically significant) compared with the Standard of Care.[6]

Red fluorescence 100% of the time reveals bacteria (≥$10^4$ CFU/g)[10]

Tracks fluorescent bacterial status pre/post treatment[5,6]

*Incorporating the MolecuLight *i:X* into standard care helps clinicians identify fluorescent bacteria and facilitates evidence-based clinician decision making which has been shown to lead to...

**89%**

**Overall reduction in costs[6]**
compared to the standard of care

### More positive outcomes
Accelerates wound closure time which could lead to reduced visits[6]

### More effective sampling
Visualises the location and distribution of bacterial load across the wound bed and periphery resulting in 54% more accurate swabbing[9]

### More savings
Facilitates more responsible decision making on dressings, antimicrobials and antibiotics at the point of care[11,12]

### Less ineffective wound treatments
Instead, informed dressing selection and objective feedback to track efficacy[11,12]

### Less unnecessary drug use
Instead, optimizes therapies and supports responsible antimicrobial stewardship[11,12]




## MolecuLight *i:X*™
## The Insight to Heal

The MolecuLight *i:X* Wound Intelligence Device offers maximum insights to facilitate evidence-based clinician decision making.[5] The power is now in your hands.

Distributed by smith&nephew

# A Revolution in Wound Care, A Revelation in Practice

MolecuLight ***i:X***™ is a wound intelligence device that meets the ever-increasing demands of modern healthcare. MolecuLight ***i:X*** supports more informed clinician treatment and decision making which as a result has been shown to accelerate healing and reduce the number of days to wound closure.[6]

## Testimonials

*"This wound would never have healed so quickly without the MolecuLight **i:X** and the gained insight to debride more frequently."*

Dr Stephan Landis, MD, FRCP(C)
Guelph General Hospital
Guelph, Canada

*"The MolecuLight **i:X** images show no red fluorescence on the gauze or wound and clinical signs and symptoms suggest nice wound healing. I will discontinue use of antimicrobial ointment and dressings and continue negative pressure wound therapy with regular gauze."*

Rose Raizman, RN-EC, MSc
Scarborough & Rouge Hospital
Toronto, Canada

*"I would not have suspected high levels of Pseudomonas on this wound. Both the Infectious Disease physician and myself were surprised when seeing the MolecuLight **i:X** images, which influenced my dressing selection."*

Rosemary Hill, BSN, CWOCN, CETN(C)
Vancouver Coastal Health
North Vancouver, Canada

| Product Code | Description | Qty | Ref |
|---|---|---|---|
| 00000000 | MolecuLight *i:X*™ | 1 | xxxxxx |
| 00000000 | MolecuLight DarkDrapes (Case of 50) | 1 | xxxxxx |
| 00000000 | MolecuLight Adapter | 1 | xxxxxx |
| 00000000 | MolecuLight Wound Protocol | 1 | xxxxxx |
| 00000000 | Extended Warranty (1 year) | 1 | xxxxxx |
| 00000000 | Accidental Damage Protection (1 year) | 1 | xxxxxx |
| 00000000 | Full Coverage Warranty including Accidental Damage Protection (2 years) | 1 | xxxxxx |

Please contact your local representative for more information

The MolecuLight ***i:X*** is manufactured by MolecuLight Inc.

MaRS Centre, South Tower
101 College St., Suite 200
Toronto, ON M5G 1L7
Canada

T +1 647.362.4684
F +1 647.362.4730
www.moleculight.com

The MolecuLight ***i:X*** is distributed by Smith&Nephew.

Smith & Nephew Medical Limited
PO BOX 81,
101 Hessle Road,
Hull, HU3 2BN

T +44 (0) 1482 225181
F +44 (0) 1482 328326
www. smith-nephew.com

© Smith-Nephew AWM-AWC-09034 | GMC00380 Rev 1.2

MolecuLight *i:X*

Distributed by smith&nephew

**References:**

**1.** Hoeflok J *et al*. Pilot clinical evaluation of surgical site infections with a novel handheld fluorescence imaging device. Proceedings of the Annual Military Health System Research Symposium (MHSRS); 2014 Aug 18-21; Fort Lauderdale, FL. **2.** Lindholm C and Searle R. Wound management for the 21st century: combining effectiveness and efficiency. Int Wound J. 2016 Jul;13 Suppl 2:5-15. **3.** Siddiqui AR and Bernstein JM. Chronic wound infection: facts and controversies. Clin Dermatol. 2010;28:519–26. **4.** Vowden P. Hard-to-heal wounds made easy. Wounds International, Schofield Healthcare Media Ltd: Norwich, UK, 2011;2. URL: http://www.woundsinternational.com. **5.** Wu YC *et al*. Handheld fluorescence imaging device detects subclinical wound infection in an asymptomatic patient with chronic diabetic foot ulcer: a case report. Int Wound J. 2016 Aug;13(4):449-53. **6.** DaCosta RS *et al*. Point-of-care autofluorescence imaging for real-time sampling and treatment guidance of bioburden in chronic wounds: first-in-human results. PLoS One. 2015 Mar 19;10(3). **7.** Raizman R. Point-of-care fluorescence imaging device guides care and patient education in obese patients with surgical site infections. Presented at: CAWC 2016. Proceedings of the Annual Canadian Association of Wound Care Conference (CAWC); 2016 Nov 3-6, Niagara Falls, ON. **8.** Raizman R. Fluorescence imaging positively predicts bacterial presence and guides wound cleaning and patient education in a series of pilonidal sinus patients. Proceedings of the Annual Wounds UK Conference; 2016 Nov 14-16; Harrogate, UK. **9.** Ottolino-Perry K *et al*. Improved detection of wound bacteria using fluorescence image guided wound sampling in diabetic foot ulcers. Int Wound J. 2017 Feb 28. doi: 10.1111/iwj.12717. **10.** Rennie MY *et al*. Clinical evaluation of fluorescence imaging in positively predicting the presence of bacteria in chronic wounds at the point of care. Proceedings of the Annual Meeting of the Society of Federal Health Professionals (AMSUS); 2016 Nov 29-Dec 2; National Harbor, MD. **11.** Hill R and Douglas JJ. Real-time bacterial fluorescence imaging guides antimicrobial stewardship in patients with diverse wounds. Proceedings of the Annual Symposium on Advanced Wound Care (SAWC); 2017 Apr 5-9; San Diego, CA. (Accepted). **12.** Landis SL *et al*. Use of fluorescence imaging in visualizing bacteria in chronic ulcers and traumatic soft tissue damage. Proceedings of the Annual Meeting of the Society of Federal Health Professionals (AMSUS); 2016 Nov 29-Dec 2; National Harbor, MD. **13.** MolecuLight Inc. MolecuLight *i:X* User Manual. 2017. **14.** MolecuLight Inc. Track wound size and bacterial presence with the MolecuLight *i:X* [Case study 0051]. 2016. **15.** Raizman (2016) Handheld real-time fluorescence imaging of bacteria guides treatment selection and timing of dressing changes in inpatients undergoing negative pressure wound therapy. Proceedings of the Innovations in Wound Healing Conference; Dec 8-11, Key Largo, FL.